Byotrol Share Discussion Threads

[football] 04/4/2024 22:03

LOL lolol lolol lolololo ??????????STD you missed Totally down from £3+ to 4p ishWhat's that?Almost 99% down from when you started ramping them?

[sikhthetech] 04/4/2024 20:44

HVO reports fy results next Tues. Polb results due as well..
Obviously 1gw and his blnx mates will be out in force ramping those.

Byot down 99% about to delist.
Blnx down 90%
Rthm down 80%
Nano down 60%
Trmr down 80%
Stu bust
GBO bust
VRS down 99%
etc
etc



Even though HVO too has questionable business models like everything else 1gw and his mates have ramped.

Coincidence.

[kumbuka] 04/4/2024 13:36

You were working very hard stupid mudbath to earn your payments.

[kumbuka] 04/4/2024 13:35

mudbath
25 Jan '13 - 09:51 - 15 of 12710
0 0 0
More.

"But now IBM and the Institute of Bioengineering and Nanotechnology say they have come up with what they're calling an antimicrobial hydrogel that can successfully fight the superbugs that are behind killers like MRSA.
In an announcement today, IBM Research and its partner on the project said that their antimicrobial hydrogel was designed to cut through diseased biofilms and almost instantly kill off drug-resistant bacteria. The collaborators on the project said that the the synthetic drug is meant for combating the growing infection problems plaguing American hospitals, because it is non-toxic, biocompatible, and biodegradable.
Normally, IBM said in its announcement, antimicrobials are used in standard household cleaners like alcohol and bleach. But those substances haven't proved effective in fighting deadly skin infections like MRSA because antibiotics are becoming less effective and standard disinfectants aren't meant for biological situations.
But the new hydrogel was created to be used in creams and other therapeutics that are meant for healing. The hydrogel can be applied to contaminated surfaces, and its positive charge instantly attracts the microbial membranes' negative charge. The bacteria is then meant to be killed by what IBM termed membrane disruption, a step that staves off any kind of resistance to the hydrogel.
Although it's not yet clear how this advancement will make its way into actual hospital and other relevant settings, research like this is meant to jump-start the commercial development of actual drugs and other therapies."

[kumbuka] 04/4/2024 13:33

Very suspicious.

Were you being paid stupid mudbath ?

[kumbuka] 04/4/2024 13:32

mudbath
25 Jan '13 - 09:24 - 14 of 12708
0 0 0
NOT GOOD NEWS ??
New hydrogel that can destroy superbugs unveiled
Posted: 24 January 2013 1614 hrs

SINGAPORE: Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research on Thursday unveiled the first-ever antimicrobial hydrogel that can destroy multidrug-resistant superbugs.
They said the gel may be used in healing wounds, medical device and contact lens coating, skin infection treatment and dental fillings.
It comprises a novel polymer material jointly developed by IBN and IBM Research in 2010.
When mixed with water and heated to body temperature, the polymers form spontaneously into a mouldable gel.
This allows the hydrogel to target multidrug-resistant biofilms at various parts of the body and surfaces without being flushed away.
Once the antimicrobial function is activated and performed, the biodegradable gel can be naturally eliminated by the body.
The researchers said tests have demonstrated the effectiveness of the novel synthetic material in eliminating various types of bacteria and fungi that are leading causes of microbial infections, and in preventing them from developing antibiotic resistance.
IBN's executive director, Professor Jackie Y Ying, said: "As a multidisciplinary research institute, IBN believes that effective solutions for complex healthcare problems can only emerge when different fields of expertise come together.
"Our longstanding partnership with IBM reflects the collaborative creativity across multiple platforms that we aim to foster with leading institutions and organisations.
"By combining IBN's biomaterials expertise and IBM's experience in polymer chemistry, we were able to pioneer the development of a new nanomaterial that can improve medical treatment and help to save lives."
Dr Yi-Yan Yang, group leader at IBN, said: "The mutations of bacteria and fungi, and misuse of antibiotics have complicated the treatment of microbial infections in recent years.
"Our lab is focused on developing effective antimicrobial therapy using inexpensive, biodegradable and biocompatible polymer material.
"With this new advance, we are able to target the most common and challenging bacterial and fungal diseases, and adapt our polymers for a broad range of applications to combat microbial infections."

Of course the discovery might prompt IBM to widen its expertise in the area by absorbing BYOTROL PLC.They are voracious when it comes to complimenting their technology.
Actual usage of the IBM tech could be some way off and could be expensive to deliver.Surrounding publicity could well act to Byotrols advantage.
Not sure yet whether the techs are competing or complimentary.

[kumbuka] 04/4/2024 13:21

Very suspicious stupid mudbath !

Were you on the payrole ?

[kumbuka] 04/4/2024 13:20

mudbath
24 Jan '13 - 10:04 - 13 of 12706
0 0 0
Anyone wondering about the potential for Byotrol to grow its revenues from the current derisory £2 million pa towards taking a significant slice of the £4 billion annual market,would do well to consider the Directorate that has been assembled recently.
Why would four such talented,relevant,successful and well connected individuals(pen portraits below) gather to oversee the future of such a nonentity of a company that Byotrol has been until recent months.
Imo it is because they understand and appreciate the value of and the potential for Byotrol.
The Directorate therefore see the current market penetration as a microcosm of the scale which lies ahead.
Recently gained significant contracts,announced with little fanfare,are just a harbinger of the growing acceptance of Byotrol as the leading,best in class product,for the global,"Hygiene Revolution".

"Dr Gary Millar, aged 51 (Chief Executive)
Gary has a PhD in Biochemistry from Glasgow University. He started his career with ICI plc, where he held several senior managerial positions. In 1998 he joined the Foseco division of Burmah Castrol plc as Supply Chain Director and was subsequently appointed Operations Director of Foseco Jersey Ltd, a private equity backed MBO, which floated on the London Stock Exchange in 2005. Between 2005 and 2007, Gary was Managing Director of Foseco Steel UK Ltd. In 2007 he was appointed Group Services Director of Foseco plc, and was a member of Foseco plc’s Executive Committee, where he played a key role in Foseco’s merger with Cookson plc.

Duncan Grosvenor, aged 34 (Finance Director)
Duncan qualified as Chartered Certified Accountant in 2001 and became F.C.C.A in 2006. He has an MBA from Oxford Brookes University and has worked as a business mentor for the Princes Trust since 2009.
Duncan joined Byotrol as Head of Finance in 2011, prior to which he was Managing Director at New Horizions Global Limited, which is a biotechnology company developing novel fermentation processes in the field of microalgae. During his time at New Horizons, Duncan developed a wide international network within the food and biotechnology industry. Before joining New Horizons Duncan was Head of Finance for LM Engineering Services Limited, a specialist structural steel engineering business and also spent six years working at Mazars providing business advisory services to a wide range of Companies.

Ralph Kugler, aged 56 (Non-Executive Chairman)
Ralph has over 25 years’ experience at the highest levels of global business. He is Board Advisor at Mars, Incorporated, and a non-executive director of Spotless Group Sas. Ralph was Chairman of Gorkana Ltd until April 2010, when he successfully led a merger with Discovery Group Holdings. Since the merger, he has been a non-executive director of the combined group – Gorkana Group Ltd. He is senior advisor for 3i plc, the global buyouts group, and advises several other companies.
Ralph was an executive director on the main Boards of Unilever plc and Unilever nv until 2008. Ralph is on the advisory board of Leeds University Business School, and a board trustee of the David Rattray Memorial Trust.

Till Medinger, aged 71 (Non-Executive Director)
Till was formerly Senior Vice President for Corporate Strategy at AstraZeneca Plc and prior to that had a long and distinguished career with Zeneca Plc and ICI Pharmaceuticals, directing business and marketing operations internationally and overseeing the launch of several global blockbuster products.
He is a past President of the Association of the British Pharmaceutical Industry and has many years international industry experience, serving on the Boards of both the European and the International Pharmaceutical Industry Federations. He has also served on the Board of the Chemical Industries Association. His business career has spanned R&D, territorial and marketing management, strategic planning, business operations, licensing and acquisitions/divestments, and public and government affairs. He has also acted as a corporate consultant to a number of high-tech companies within the US and the UK.
He is Chairman of PhotoBiotics Limited and a Non-executive Director of Datapharm Communications Ltd. He has a Doctorate in Chemistry from Oxford University."

After several frustrating years,Byotrol is not the most obvious investment.
Imo this status will change rapidly over coming months.

[kumbuka] 04/4/2024 13:11

mudbath
19 Jan '13 - 22:24 - 8 of 12705
0 0 0
We can be very confident that Byotrol revenues are about to increase exponentially.
Imo it is just a case of HOW FAST and HOW FAR.
Byotrol is not quite at the stage of being a MUST HAVE component,yet its anti-microbial technology is without doubt gaining what could well prove to be unstoppable recognition and momentum.

When Byotrol recently won the Best New Product award from the Society of Food Hygiene and Technology for its ability to protect healthcare environments against infection,it was judged by the Society to have significantly improved hygiene in food manufacturing, preparation and retail.

Indeed,Richard Werran, Managing Director of Cert ID Europe, commented: "Our auditors see the inside of factories worldwide, and if there is one thing we could recommend to significantly improve hygiene it would be to use Byotrol."

I remain strongly convinced that Byotrol's recent remarkable progress towards becoming a serious global player in the £4 billion anti-microbial biocidal concentrates arena is being totally overlooked.

INTERESTING !!

[kumbuka] 04/4/2024 13:10

mudbath
12 Jan '13 - 10:06 - 7 of 12704
0 0 0
The covering analyst at Finncap,Dr.Keith Redpath,suggests that Byotrol might lose £700k over the full year to Mar 31st 2013.This would indicate a loss of just £23k for the current six months.
If correct,the losses for the past 3 six monthly trading periods would read:-
March 2012= £1377k
Sept 2012= £677k
March 2013= £23k
An impressive trend then,which if maintained, could see BYOT report profits of over £500k for the six months to Sept 2013;although Byotrol house brokers are forecasting a more modest 300k profit for the full year.
Reading between the lines,BYOT are looking at a surge in orders.Why else would they be seeking to put in place a significant invoice discounting facility with their bankers.
With an IDF in place,Finncap predict BYOT could turn cash flow neutral within the current trading period,possibly then precluding the need for a further large cash raising exercise

After several disappointing years,Byotrol seems to be coming good at quite a pace,and imo this pace could quicken
Finncap have in place an initial share price target of 15 pence.
The share price chart currently looks strong and it could be that such a level is soon tested.

A very interesting investment opportunity.

[kumbuka] 04/4/2024 13:00

Looks to me like you are still being paid stupid mudbath.

[mudbath] 04/4/2024 12:58

The "FOR SALE" sign might well be flashing, for a disposal would help extricate Traynor from the need to provide any further "direction".
He can console himself though in the knowledge that he is just the latest in a succession of Byotrol CEOs who have failed to generate any sales momentum.
What on earth happened to that "ready made sales team" over at Medimark Scientific that we splurged £millions acquiring?

[kumbuka] 04/4/2024 12:54

Stupid mudbath were you paid to RAMP BYOT ?

[kumbuka] 04/4/2024 12:52

How clear do you need it spelt out pigsbladder ?

You have lost a lot of money and you deserve to after your mindless ramping.

[football] 04/4/2024 12:38

By DT saying this is going private did he hope to flush out bidders for Byotrol?

[clocktower] 04/4/2024 11:53

The last full year accounts showed Royalty and licensing income of £281k write off all the stock and run the business in a skeleton fashion and within a couple of years you would be sitting pretty if you could take control at less than 0.15

As a shell company with this level of assured income it is worth more than it's current level.

[mudbath] 04/4/2024 10:32

Tight quote currently on 1million BYOT
Sell 0.06
Buy 0.061

[mudbath] 04/4/2024 10:24

Yet with a market cap this morning for Byotrol of just under £318,000, the swing to oversold and possibly greatly undervalued seems to be somewhat extreme in nature.
I remain exceedingly tempted to add; for surely there will be at least one vulture circling the carnage.

[cliffpeat] 04/4/2024 08:55

Government "enquiries" often splutter out with no one going to jail and serious voices telling us "what has been learnt from this".

So, what have I learned from the time and money I have invested in Byotrol?

1. To do the reading, understanding and research. Particularly be aware that if something is "TL/DR" it is probably important and may affect my own position (e.g. Special Resolutions in Sept 23 - and accounting method for IP licensing royalties etc.).

2. Researching something and ignoring apparent "red flags". (e.g. Byotrol insubstantial trading "partners" (post 10678); )

3. Red flag: Intangible assets that are a high % of total shareholder equity (and inc. "customer relationships", "brands" "development costs".

4. Red flag: Ground-breaking research and patent into seaweed extracts without any associated commercial options being announced. Post 11367

5. Simple research and calculations that suggest no commercial grasp on target markets (e.g. post 10581 re UK Vet market)

6. Red flag: Informed research by other posters 1gw et al that indicates effort by company without results (roll out of Anigene etc.)

7. Red flag: Board that blames external factors for inability to raise funding when all the signs are that the management has not performed.

8. Perceiving that the technical prowess is not matched by the commercial/trading abilities they serve (e.g. Zytec plc, Indigovision plc; post 10572)

9. "Betting" an increasing loss on the shares against an unlikely recovery of the company.

Printed and stuck to my study door!
GLA

[football] 04/4/2024 08:34

Why are so many public companies delisting?

RedX today joined C4X Discovery and Byotrol in announcing plans to quit London Stock Exchange’s AIM. Chris Maguire looks at why that is

[supernumerary] 03/4/2024 21:43

Goferit!

I guess it wouldn't be that hard to acquire a blocking position, although the necessary buying might move the price out of reach, but what then?

I suppose one could just cut the Gordian knot - fire everyone who wasn't directly involved in the pet care business, sell off any unused ip, put in a decent manager who doesn't have inflated expectations, and run it as an animal care business...

[loafofbread] 03/4/2024 21:30

mudbath,

Tell me about it.

One of my positions is 1M in a ISA that cost 4p or £40,000 3 years ago?

Tomorrow, I can double that position for £1,000.

[sikhthetech] 03/4/2024 19:58

Microscope/Mudbath,

I had been thinking of taking a punt as well, using some of the betting profits.
There's still several weeks until the vote and anything can happen.